Back

Inotersen improved quality of life, polyneuropathy and cardiomyopathy in a diverse group of patients with hereditary transthyretin amyloidosis in the phase 3 study NEURO-TTR

25 August 2018 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Poster Session 1 - Cardiomyopathies: various aspects Infiltrative Myocardial Disease ESC Premium Access ESC Congress 2018

About the speaker

Photo
Doctor Steve Hughes

Ionis Pharmaceuticals Inc, Carlsbad (United States of America)

9 More presentations in this session

Presentation thumbnail
In silico finite element modeling of longitudinal wave propagation for assessment of myocardial stiffness: comparison with findings from patients with cardiac amyloidosis
Doctor O. Anupraiwan (Nonthaburi, TH)
Abstract
Presentation thumbnail
Pathology of conduction tissue in cardiac amyloid: correlation with arrhythmic manifestations
Associate Professor A. Frustaci (Rome, IT)
Presentation thumbnail
Intramyocardial inflammation correlates with poor prognosis in patients with cardiac AL amyloidosis
Doctor F. Escher (Berlin, DE)
Abstract
Presentation thumbnail
Hereditary transthyretin amyloidosis is associated with significant disease burden: analysis of the baseline characteristics of patients from the phase 3 study NEURO-TTR
Professor T. Damy (Creteil, FR)
Abstract
Presentation thumbnail
Amplitude of inverted T-waves in arrhythmogenic cardiomyopathy in specific right ventricular leads.
Associate Professor S. Peters (Elze, DE)

Access the full session

Session thumbnail
Poster Session 1 - Cardiomyopathies: various aspects

The Event

Event poster

ESC Congress 2018

25 August - 29 August 2018

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources